Perhaps AMLN is now sufficiently satisfied with LAR that they no longer need the intranasal idea as a backup.
After being a serious AMLN bull since 1999, I no longer own a single share. LAR concerns and the impending Liraglutide have scared me off, along with a lofty valuation.
Dew, I'm curious to know if you have any thoughts on Liraglutide vs. Byetta LAR.
Market Data 
Markets 
AI
